UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 353

Sortiert nach

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

The New England journal of medicine, 2013-09, Vol.369 (11), p.999-1010

2013

Volltextzugriff (PDF)

The FDA and PLATO Investigators death lists: Call for a match

International journal of clinical practice (Esher), 2021-07, Vol.75 (7), p.e14105-n/a

2021

Volltextzugriff (PDF)

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

Journal of the American College of Cardiology, 2015-05, Vol.65 (20), p.2211-2221

2015

Volltextzugriff (PDF)

FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction

Reviews in cardiovascular medicine, 2021-09, Vol.22 (3), p.553-555

2021

Volltextzugriff (PDF)

A web‐based tailored nursing intervention (TAVIE en m@rche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial

Journal of advanced nursing, 2019-11, Vol.75 (11), p.2727-2741

2019

Volltextzugriff (PDF)

Primary Causes of Death Reported to the FDA Suggest Less Ticagrelor Mortality Benefit than the List Issued to the PLATO Trial Investigators

Reviews in cardiovascular medicine, 2022-04, Vol.23 (4), p.132

2022

Volltextzugriff (PDF)

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

The Lancet (British edition), 2014-09, Vol.384 (9949), p.1187-1195

2014

Volltextzugriff (PDF)

Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction

Journal of the American College of Cardiology, 2016-08, Vol.68 (7), p.715-723

2016

Volltextzugriff (PDF)

Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial

Catheterization and cardiovascular interventions, 2017-02, Vol.89 (2), p.190-198

2017

Volltextzugriff (PDF)

Misreported Cancer Deaths in PLATO Trial

Journal of clinical medicine, 2021-07, Vol.10 (14), p.3140

2021

Volltextzugriff (PDF)

Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study)

The American journal of cardiology, 2019-12, Vol.124 (12), p.1813-1820

2019

Volltextzugriff (PDF)

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison

Platelets (Edinburgh), 2022-02, Vol.33 (2), p.298-303

2022

Volltextzugriff (PDF)

Prognostic impact of the residual SYNTAX score on in-hospital outcomes in patients undergoing primary percutaneous coronary intervention

Catheterization and cardiovascular interventions, 2016-11, Vol.88 (5), p.740-747

2016

Volltextzugriff (PDF)

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non–ST-segment elevation acute coronary syndrome

The American heart journal, 2013-06, Vol.165 (6), p.918-925.e2

2013

Volltextzugriff (PDF)

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2020-08, Vol.324 (8), p.761

2020

Volltextzugriff (PDF)

Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Circulation (New York, N.Y.), 2016-05, Vol.133 (21), p.2094-2098

2016

Volltextzugriff (PDF)

Cardiac resident nestin+ cells participate in reparative vascularisation

Journal of cellular physiology, 2013-09, Vol.228 (9), p.1844-1853

2013

Volltextzugriff (PDF)

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update

Circulation (New York, N.Y.), 2021-02, Vol.143 (6), p.583-596

2021

Volltextzugriff (PDF)

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update

Circulation (New York, N.Y.), 2018-07, Vol.138 (5), p.527-536

2018

Volltextzugriff (PDF)

Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years

Open heart, 2024-06, Vol.11 (1), p.e002679

2024

Volltextzugriff (PDF)

Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Journal of the American Heart Association, 2017-11, Vol.6 (11), p.n/a

2017

Volltextzugriff (PDF)

Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non–ST-Elevation Myocardial Infarction (ACCOAST) study

The American heart journal, 2015-11, Vol.170 (5), p.1025-1032.e2

2015

Volltextzugriff (PDF)

Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial

Journal of the American College of Cardiology, 2019-12, Vol.74 (22), p.2713-2723

2019

Volltextzugriff (PDF)

1 – 25 von 353

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(339)
Mit Volltextzugriff
(326)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(231)
Life Sciences & Biomedicine
(226)
Humans
(158)
Cardiovascular System & Cardiology
(154)
Cardiac & Cardiovascular Systems
(143)
Male
(113)
Female
(102)
Middle Aged
(77)
Aged
(64)
Biological And Medical Sciences
(62)
Animals
(60)
Treatment Outcome
(58)
Medical Sciences
(56)
Cardiovascular
(50)
Stents
(39)
Cardiology
(38)
Time Factors
(38)
Percutaneous Coronary Intervention
(35)
Cardiology. Vascular System
(33)
Heart Attacks
(32)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

The FDA and PLATO Investigators death lists: Call for a match

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction

A web‐based tailored nursing intervention (TAVIE en m@rche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial

Digital Tool-Assisted Hospitalization Detection in the Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention Study Compared to Traditional Site-Coordinator Ascertainment: Intervention Study

Primary Causes of Death Reported to the FDA Suggest Less Ticagrelor Mortality Benefit than the List Issued to the PLATO Trial Investigators

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction

Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial

Misreported Cancer Deaths in PLATO Trial

Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study)

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison

Prognostic impact of the residual SYNTAX score on in-hospital outcomes in patients undergoing primary percutaneous coronary intervention

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non–ST-segment elevation acute coronary syndrome

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial

Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Cardiac resident nestin+ cells participate in reparative vascularisation

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update

Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years

Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non–ST-Elevation Myocardial Infarction (ACCOAST) study

Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial

Suchergebnisse filtern